Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (810)	6/2/1999 11:34:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1386

Stephen - it's productive and on the road to profitability, but it's darn hard to get a stock to move without Wall Street analytical coverage. That's the simple truth that has made the company step up shareholder communications this year -- not only for individual shareholders, but for institutional shareholders and, of course, for those elusive Street analysts. One good thing though -- they run in herds. After the first one finds PARS, others will follow. -Ariella

To: Stephen D. Wilson who wrote (810)	6/3/1999 9:45:00 AM
From: johnny weissman	Read Replies (4) \| Respond to of 1386

Knowledgeable people on this thread have various explanations for PARS'--what's the word?... execrable--performance. Here's mine: PARS is a penny stock. It cannot hold its gains. That category, that identity in the stock world, over-rides the company/sector reality. Only a buy-out can jack this stock up, imo. Like most stocks, it probably has no right to have gone public. This is despite any good work it's doing. Only a very few people will ever benefit from PARS being a public company. I hope I eat my words someday ...